Lake Street Capital Reaffirms Buy Rating for OptimizeRx (NASDAQ:OPRX)

OptimizeRx (NASDAQ:OPRX)‘s stock had its “buy” rating restated by equities research analysts at Lake Street Capital in a report released on Tuesday,Benzinga reports. They currently have a $11.00 target price on the stock. Lake Street Capital’s price target suggests a potential upside of 122.67% from the stock’s current price.

Several other brokerages also recently weighed in on OPRX. Royal Bank of Canada reduced their price target on OptimizeRx from $14.00 to $7.00 and set an “outperform” rating for the company in a report on Thursday, November 14th. JMP Securities reduced their price objective on shares of OptimizeRx from $16.00 to $8.00 and set a “market outperform” rating for the company in a research note on Thursday, November 14th. Stifel Nicolaus cut their price target on shares of OptimizeRx from $13.00 to $8.00 and set a “buy” rating on the stock in a report on Thursday, November 14th. B. Riley lowered their price objective on OptimizeRx from $17.00 to $13.00 and set a “buy” rating on the stock in a research report on Tuesday. Finally, Stephens assumed coverage on OptimizeRx in a research note on Friday, December 20th. They issued an “equal weight” rating and a $5.50 price target for the company. Two equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat, OptimizeRx presently has an average rating of “Moderate Buy” and an average price target of $9.19.

OptimizeRx Stock Up 2.3 %

OPRX stock opened at $4.94 on Tuesday. The business has a 50 day moving average of $5.28 and a 200 day moving average of $7.67. The firm has a market cap of $91.00 million, a PE ratio of -3.71 and a beta of 1.34. OptimizeRx has a twelve month low of $3.78 and a twelve month high of $16.65. The company has a quick ratio of 3.23, a current ratio of 3.23 and a debt-to-equity ratio of 0.29.

Insider Buying and Selling

In other OptimizeRx news, CEO William J. Febbo acquired 20,000 shares of the stock in a transaction dated Thursday, December 12th. The shares were purchased at an average price of $5.01 per share, for a total transaction of $100,200.00. Following the purchase, the chief executive officer now directly owns 601,253 shares of the company’s stock, valued at approximately $3,012,277.53. This trade represents a 3.44 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. 6.10% of the stock is currently owned by corporate insiders.

Institutional Trading of OptimizeRx

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. BNP Paribas Financial Markets grew its position in shares of OptimizeRx by 189.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 3,690 shares of the company’s stock valued at $28,000 after acquiring an additional 2,414 shares during the period. Quest Partners LLC grew its holdings in OptimizeRx by 15,965.6% during the third quarter. Quest Partners LLC now owns 9,800 shares of the company’s stock valued at $76,000 after purchasing an additional 9,739 shares during the period. Connors Investor Services Inc. increased its position in OptimizeRx by 15.1% in the second quarter. Connors Investor Services Inc. now owns 19,107 shares of the company’s stock worth $191,000 after buying an additional 2,500 shares in the last quarter. Barclays PLC lifted its position in shares of OptimizeRx by 358.5% during the 3rd quarter. Barclays PLC now owns 26,934 shares of the company’s stock valued at $208,000 after buying an additional 21,060 shares in the last quarter. Finally, Squarepoint Ops LLC bought a new position in shares of OptimizeRx during the 2nd quarter valued at approximately $282,000. 76.47% of the stock is owned by hedge funds and other institutional investors.

OptimizeRx Company Profile

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.